

Bruno Moulin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/848292/publications.pdf>

Version: 2024-02-01

124
papers

9,182
citations

41344

49
h-index

40979

93
g-index

143
all docs

143
docs citations

143
times ranked

9403
citing authors

#	ARTICLE	IF	CITATIONS
1	Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis. <i>Kidney International Reports</i> , 2022, 7, 343-349.	0.8	6
2	Response to a Letter to the Editor regarding "Granulomatous inflammation and hypercalcemia in patients with severe systemic oxalosis" by Perrin et al., <i>KI Reports</i> 2021. <i>Kidney International Reports</i> , 2022, 7, 931.	0.8	0
3	A gain-of-function variant in the Wiskott-Aldrich syndrome gene is associated with a MYH9-related disease-like syndrome. <i>Blood Advances</i> , 2022, 6, 5279-5284.	5.2	2
4	Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients" Results from a proof-of-concept study. <i>American Journal of Transplantation</i> , 2021, 21, 329-337.	4.7	24
5	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	5.2	24
6	Cytokine release syndrome-associated encephalopathy in patients with COVID-19. <i>European Journal of Neurology</i> , 2021, 28, 248-258.	3.3	114
7	Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.	0.7	11
8	Hemodynamic Management During Kidney Transplantation: A French Survey. <i>Transplantation Proceedings</i> , 2021, 53, 1450-1453.	0.6	1
9	Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1644-1651.	6.0	10
10	Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.	1.6	3
11	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. <i>Kidney International</i> , 2021, 99, 1498-1500.	5.2	163
12	Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 1487-1489.	5.2	126
13	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	2.7	37
14	Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 158-169.	1.0	34
15	High-flow arteriovenous fistula and hemodynamic consequences at 1 year after kidney transplantation. <i>Seminars in Dialysis</i> , 2021, , .	1.3	0
16	Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort. <i>Transplantation</i> , 2020, 104, 2148-2157.	1.0	6
17	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 259-266.	1.1	7
18	Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. <i>BMC Nephrology</i> , 2020, 21, 405.	1.8	1

#	ARTICLE	IF	CITATIONS
19	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	5.2	213
20	In-depth virological assessment of kidney transplant recipients with COVID-19. <i>American Journal of Transplantation</i> , 2020, 20, 3162-3172.	4.7	68
21	End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1630.	4.8	24
22	The Authors Reply. <i>Kidney International Reports</i> , 2019, 4, 1658-1659.	0.8	1
23	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
24	Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. <i>Journal of Infection</i> , 2019, 79, 56-60.	3.3	40
25	Pregnancy in a Kidney Transplant Woman Under Treatment With Eculizumab for Atypical Hemolytic Uremic Syndrome: Is It Safe?. <i>Kidney International Reports</i> , 2019, 4, 733-739.	0.8	10
26	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. <i>Kidney International</i> , 2019, 96, 231-244.	5.2	69
27	Transplant center characteristics associated with living donor kidney transplantation: a cohort study with a hierarchical modeling approach. <i>Transplant International</i> , 2019, 32, 865-875.	1.6	1
28	Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study. <i>Transplant Infectious Disease</i> , 2019, 21, e13058.	1.7	13
29	Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. <i>PLoS ONE</i> , 2019, 14, e0212931.	2.5	13
30	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 285-291.	2.0	23
31	Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 326-334.	6.1	64
32	Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort. <i>Transplantation</i> , 2018, 102, 860-867.	1.0	18
33	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1603-1613.	6.1	83
34	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. <i>Transplant International</i> , 2017, 30, 256-265.	1.6	30
35	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
36	Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1897-1905.	1.0	29

#	ARTICLE	IF	CITATIONS
37	Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins. <i>Transplant Immunology</i> , 2017, 45, 48-52.	1.2	6
38	A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1663-1670.	4.5	32
39	Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. <i>American Journal of Transplantation</i> , 2017, 17, 1370-1379.	4.7	85
40	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. <i>American Journal of Transplantation</i> , 2017, 17, 1008-1019.	4.7	13
41	Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. <i>Transplant International</i> , 2017, 30, 29-40.	1.6	27
42	How can a vascular surgeon help in kidney transplantation. <i>Journal of Cardiovascular Surgery</i> , 2017, 58, 351-359.	0.6	1
43	Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-6.	0.3	8
44	French law: what about a reasoned reimbursement of serum vitamin D assays?. <i>Psychologie & Neuropsychiatrie Du Vieillissement</i> , 2016, 14, 377-382.	0.2	7
45	Ruling out nosocomial transmission of <i>Cryptosporidium</i> in a renal transplantation unit: case report. <i>BMC Infectious Diseases</i> , 2016, 16, 363.	2.9	15
46	Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study. <i>BMC Nephrology</i> , 2016, 17, 58.	1.8	1
47	A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 223-229.	2.0	21
48	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. <i>American Journal of Transplantation</i> , 2016, 16, 2670-2675.	4.7	51
49	One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation. <i>Transplantation</i> , 2016, 100, 391-399.	1.0	157
50	Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients. <i>Kidney International</i> , 2016, 89, 1136-1143.	5.2	31
51	Eight-year results of the Spiesser study, a randomized trial comparing <i>de novo</i> sirolimus and cyclosporine in renal transplantation. <i>Transplant International</i> , 2016, 29, 41-50.	1.6	32
52	Intraoperative Pleth Variability Index Is Linked to Delayed Graft Function After Kidney Transplantation. <i>Transplantation Proceedings</i> , 2016, 48, 2615-2621.	0.6	11
53	Pre-transplant end-stage renal disease-related immune risk profile in kidney transplant recipients predicts post-transplant infections. <i>Transplant Infectious Disease</i> , 2016, 18, 415-422.	1.7	39
54	Advagraf [®] , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. <i>Transplant International</i> , 2016, 29, 860-869.	1.6	34

#	ARTICLE	IF	CITATIONS
55	B7 ¹ Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. <i>Journal of the American Society of Nephrology</i> ; JASN, 2016, 27, 2520-2527.	6.1	75
56	Comparing the Bbs10 complete knockout phenotype with a specific renal epithelial knockout one highlights the link between renal defects and systemic inactivation in mice. <i>Cilia</i> , 2015, 4, 10.	1.8	29
57	The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience. <i>PLoS ONE</i> , 2015, 10, e0119156.	2.5	41
58	Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations. <i>American Journal of Transplantation</i> , 2015, 15, 800-805.	4.7	62
59	Fibrosis Progression According to Epithelial-Mesenchymal Transition Profile: A Randomized Trial of Everolimus Versus CsA. <i>American Journal of Transplantation</i> , 2015, 15, 1303-1312.	4.7	61
60	ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 1028-1038.	4.7	92
61	Anti-Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. <i>Journal of Immunology</i> , 2015, 194, 5129-5138.	0.8	99
62	Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3842-3852.	3.9	27
63	Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study. <i>Journal of Transplantation</i> , 2014, 2014, 1-8.	0.5	6
64	Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 109-118.	6.0	105
65	Genetics and Outcome of Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology</i> ; CJASN, 2013, 8, 554-562.	4.5	567
66	Parathyroid Hormone-Related Protein Is a Mitogenic and a Survival Factor of Mesangial Cells from Male Mice: Role of Intracrine and Paracrine Pathways. <i>Endocrinology</i> , 2013, 154, 853-864.	2.8	32
67	Impaired platelet P2Y ₁₂ inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1994-2002.	0.7	36
68	Knockdown of parathyroid hormone related protein in smooth muscle cells alters renal hemodynamics but not blood pressure. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F333-F342.	2.7	25
69	Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score. <i>Journal of Clinical Oncology</i> , 2013, 31, 1302-1309.	1.6	122
70	Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome. <i>American Journal of Transplantation</i> , 2013, 13, 663-675.	4.7	224
71	Persistent Hyperparathyroidism Is a Major Risk Factor for Fractures in the Five Years After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 2653-2663.	4.7	122
72	Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome. <i>New England Journal of Medicine</i> , 2013, 368, 2169-2181.	27.0	1,258

#	ARTICLE	IF	CITATIONS
73	Risk Factors for BK Virus Infection in the Era of Therapeutic Drug Monitoring. <i>Transplantation</i> , 2013, 95, 1498-1505.	1.0	103
74	Factors Predictive of Medication Nonadherence After Renal Transplantation. <i>Transplantation</i> , 2013, 95, 326-332.	1.0	68
75	Localization of Tubular Adaptation to Renal Sodium Loss in Gitelman Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 472-478.	4.5	14
76	Correction of Postkidney Transplant Anemia Reduces Progression of Allograft Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 360-368.	6.1	110
77	Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3651-3659.	0.7	10
78	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. <i>Transplantation</i> , 2012, 94, 784-793.	1.0	45
79	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. <i>Kidney International</i> , 2012, 82, 454-464.	5.2	454
80	Evaluation of Protocol Biopsy Utility 12 Months after Renal Transplantation: A Multicenter Observational Analysis. <i>Journal of Transplantation</i> , 2012, 2012, 1-9.	0.5	8
81	Association of Estimated GFR With Platelet Inhibition in Patients Treated With Clopidogrel. <i>American Journal of Kidney Diseases</i> , 2012, 59, 777-785.	1.9	52
82	Epidemiology of Posttransplant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas. <i>American Journal of Transplantation</i> , 2012, 12, 682-693.	4.7	166
83	Five-Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study. <i>American Journal of Transplantation</i> , 2012, 12, 1801-1810.	4.7	48
84	Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2011, 57, 399-408.	2.8	121
85	Incidence and Risk Factors of Glucose Metabolism Disorders in Kidney Transplant Recipients: Role of Systematic Screening by Oral Glucose Tolerance Test. <i>Transplantation</i> , 2011, 91, 757-764.	1.0	72
86	Impact of pretransplant dialysis modality on posttransplant diabetes mellitus after kidney transplantation. <i>Clinical Transplantation</i> , 2011, 25, 794-799.	1.6	28
87	Post-transplant Lymphoproliferative Disorders: Determination of Donor/Recipient Origin in a Large Cohort of Kidney Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 1260-1269.	4.7	48
88	Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF: Four-Year Results of the Postconcept Study. <i>American Journal of Transplantation</i> , 2011, 11, 1665-1675.	4.7	84
89	Giant colonic ulcer and pseudopolyps in an immunodepressed patient. <i>Endoscopy</i> , 2011, 43, 926-927.	1.8	1
90	Spectrum of Mutations in Gitelman Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 693-703.	6.1	190

#	ARTICLE	IF	CITATIONS
91	Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. <i>Kidney International</i> , 2011, 79, 1013-1025.	5.2	46
92	Bardet-Biedl Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 22-29.	4.5	103
93	Gestational Choriocarcinoma Transmission Following Multiorgan Donation. <i>American Journal of Transplantation</i> , 2010, 10, 2541-2546.	4.7	24
94	Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 721-6.	4.7	280
95	Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. <i>Transplant International</i> , 2010, 23, 1084-1093.	1.6	68
96	Renal biopsy practice in France: results of a nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3579-3585.	0.7	30
97	Renal Transplantation in Patients with Sarcoidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2101-2108.	4.5	43
98	Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 967-976.	0.7	87
99	European consensus statement on the terminology used in the management of lupus glomerulonephritis. <i>Lupus</i> , 2009, 18, 257-263.	1.6	131
100	Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study. <i>American Journal of Transplantation</i> , 2009, 9, 1115-1123.	4.7	246
101	Interstitial Fibrosis Quantification in Renal Transplant Recipients Randomized to Continue Cyclosporine or Convert to Sirolimus. <i>American Journal of Transplantation</i> , 2009, 9, 2552-2560.	4.7	60
102	Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus. <i>Transplantation</i> , 2009, 88, 69-76.	1.0	75
103	Chronic Lymphocytic Leukemia: A Hazardous Condition Before Kidney Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 2471-2475.	4.7	7
104	Effect of the shipment of cadaveric renal allografts on allograft survival. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1054-1060.	0.7	6
105	Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant. <i>Clinical Transplantation</i> , 2007, 21, 295-300.	1.6	9
106	Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin, Mycophenolate Mofetil and a 6-Month Course of Steroids. <i>American Journal of Transplantation</i> , 2007, 7, 2522-2531.	4.7	160
107	Tolerability of Enteric-Coated Mycophenolate Sodium to 1 Year in Combination With Cyclosporine and Corticosteroids in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2006, 38, 2860-2863.	0.6	7
108	Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. <i>British Journal of Haematology</i> , 2006, 134, 602-612.	2.5	50

#	ARTICLE	IF	CITATIONS
109	Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The 'Reference' Study. American Journal of Transplantation, 2006, 6, 2725-2734.	4.7	52
110	Post-Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry. American Journal of Transplantation, 2006, 6, 2735-2742.	4.7	237
111	Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrology Dialysis Transplantation, 2006, 21, 1053-1059.	0.7	83
112	Simultaneous Development of Lymphoma in Recipients of Renal Transplants from a Single Donor: Donor Origin Confirmed by Human Leukocyte Antigen Staining and Microsatellite Analysis. Transplantation, 2005, 79, 79-84.	1.0	16
113	Tenofovir-induced acute renal failure in an HIV patient with normal renal function. Nephrology Dialysis Transplantation, 2005, 20, 473-474.	0.7	26
114	Is Sirolimus Responsible for Proteinuria?. Transplantation Proceedings, 2005, 37, 2828-2829.	0.6	17
115	Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide. Blood Pressure, 2004, 13, 18-24.	1.5	9
116	Néphropathie interstitielle immuno-allergique Drug-induced acute interstitial nephritis. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2003, 12, 306-312.	0.1	6
117	Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrology Dialysis Transplantation, 2003, 18, 2147-2153.	0.7	66
118	A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation, 2003, 75, 844-851.	1.0	150
119	Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation, 2003, 76, 930-937.	1.0	99
120	Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF-containing Triple Therapy. American Journal of Transplantation, 2002, 2, 48-56.	4.7	226
121	Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. Transplant International, 2000, 13, S388-S393.	1.6	19
122	Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. Transplant International, 2000, 13, S388-S393.	1.6	10
123	Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney International, 1992, 42, 127-135.	5.2	167
124	Atrial natriuretic peptide in the renal response to an acute protein load. International Journal of Clinical Pharmacology Research, 1990, 10, 211-6.	0.4	3